Document is current
Any future updates will be listed below
-
Authors
Jensen, Maj-Britt https://orcid.org/0000-0001-5348-3040
Nielsen, Torsten O. https://orcid.org/0000-0003-3769-2517
Bartlett, John https://orcid.org/0000-0002-0347-3888
Lænkholm, Anne-Vibeke https://orcid.org/0000-0003-2166-8686
Shepherd, Lois
Ejlertsen, Bent https://orcid.org/0000-0001-8761-714X
- License Information
-
More Information
Article History
Received: 6 September 2024
Accepted: 20 February 2025
First Online: 10 March 2025
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests: Advisory board, Novartis (MJ). Grants from Canadian Cancer Society during the conduct of the study as well as personal fees from Bioclassifier outside the submitted work, a patent for Prosigna issued, licensed, and with royalties paid from Veracyte (TON). Consultancies with Cerca Biotech and Biotheranostics as well as multiple patents in biomarkers, all outside the submitted work (JB). Institutional grant from AstraZeneca, personal grants from AstraZeneca, advisory board MSD and travel expenses from Daiichi Sankyo and Astra Zeneca (AVL). Institutional grants from the Danish Cancer Society, Astra Zeneca, Daiichi Sankyo, Eli Lilly, MSD, Novartis and Pfizer, and travel expenses from Daiichi Sankyo, MSD, Pfizer (BE).
